DPP-IV inhibitors, GLP-1 analogues to see strongest growth among Type 2 diabetes drugs through 2020, study finds
BURLINGTON, Mass. — Two classes of drugs for treating Type 2 diabetes will experience the biggest growth in market share of all classes of drugs for the condition, according to a new study by Decision Resources.
The study found that DPP-IV inhibitors and GLP-1 analogues would experience the biggest growth in market share among all drug classes, with a combined market share that will increase from 20% in 2010 to 47% in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The report found that Merck & Co.'s Januvia (sitagliptin) dominates DPP-IV drugs and will consolidate its position, while GLP-1 analogues will have a strong position as well, with Novo Nordisk's Victoza (liraglutide) having the opportunity to edge up due to delays in the launch of Bydureon (exenatide), a once-weekly GLP-1 analogue made by Eli Lily & Co., Amylin Pharmaceuticals and Alkermes.